Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide Journal Article


Authors: Enting, R. H.; Demopoulos, A.; Deangelis, L. M.; Abrey, L. E.
Article Title: Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
Abstract: The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.
Keywords: adult; cancer survival; clinical article; controlled study; treatment outcome; aged; disease-free survival; middle aged; survival analysis; retrospective studies; clinical trial; cancer recurrence; salvage therapy; cancer combination chemotherapy; drug efficacy; cancer radiotherapy; combined modality therapy; cytarabine; methotrexate; rituximab; temozolomide; brain neoplasms; dacarbazine; controlled clinical trial; cohort studies; neoplasm recurrence, local; anemia; leukopenia; thrombocytopenia; vincristine; drug resistance, neoplasm; procarbazine; central nervous system neoplasms; lymphoma, b-cell; cancer regression; antigens, cd20; antibodies, monoclonal; immunotherapy; antigens, neoplasm; antineoplastic agents, alkylating; remission induction; acute toxicity; brain lymphoma; drug evaluation; eye neoplasms; life tables; humans; human; male; female; priority journal; article
Journal Title: Neurology
Volume: 63
Issue: 5
ISSN: 0028-3878
Publisher: Lippincott Williams & Wilkins  
Date Published: 2004-09-14
Start Page: 901
End Page: 903
Language: English
PROVIDER: scopus
PUBMED: 15365145
DOI/URL:
Notes: Neurology -- Cited By (since 1996):119 -- Export Date: 16 June 2014 -- CODEN: NEURA C2 - 15365145 -- Source: Scopus
Citation Impact
MSK Authors
  1. Lauren E Abrey
    278 Abrey